The disease epidemiology covered in the report provides historical as well as forecasted ARDS epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

1. ARDS Market
Presented by- DelveInsight Business Research

3. What are the ARDS Market Insights?
Furthermore, Pancuronium and Vecuronium are the most commonly used NMBAs for the
management of ARDS. The use of NMBAs in the ICU, especially in ARDS patients, is not marginal.
A national US survey performed after 1995, American College of Critical Care Medicine/Society of
Critical Care Medicine (ACCM/SCCM) guidelines implementation showed that Vecuronium
(Organon Pharmaceuticals) was routinely used in 18.6% and frequently in 30.5% of ICU patients.
However, there are inherent risks to the use of NMBAs in patients in the ICU. Unrecognized
ventilator disconnections can quickly lead to hypoxemia and hypercarbia and cause
cardiopulmonary collapse. Inadequate sedation and analgesia in a paralyzed patient can cause
extreme psychologic distress.

4. In ARDS, the evolution of systemic and pulmonary inflammation in the 1st week of mechanical
ventilation determines the physiologic progression (resolving vs unresolving) and the outcome of
the disease. Glucocorticoids as end-effectors of the hypothalamic-pituitary-adrenal axis are the
most important physiologic inhibitors of inflammation, affecting hundreds of genes involved in
stress-related homeostasis. At the cellular level, glucocorticoids exert their effects by activating
cytoplasmic heat shock protein-complexed glucocorticoid receptors, which in turn, interact with
activated nuclear factor-κB to prevent DNA binding and subsequent transcriptional activity.

5. It is expected that the ARDS Market size of the currently
available supportive therapies for the treatment of ARDS shall
experience steady growth throughout the study period [2017–
2030]. Overall, the increasing incidence, awareness of the
disease and promising emerging pipeline therapies will propel the
market size forward during the forecast period of 2020–2030.

6. ● The US
● EU5 (Germany, France, Italy, Spain,
and the United Kingdom)
● Japan
How Many Regions Are
Covered?

7. The ARDS market outlook of the report
helps to build the detailed
comprehension of the historic, current,
and forecasted ARDS market trends by
analyzing the impact of current therapies
on the market, unmet needs, drivers and
barriers and demand of better
technology.
ARDS Market
Outlook

8. Despite decades of research, treatment options for ARDS are restricted.
Supportive care with mechanical ventilation remains the mainstay of
management. There are relatively few treatments available for ARDS.
Other treatment options, which the patients with ARDS are subjected to
generally include supplemental oxygen, prone positioning, use of
paralytics, fluid management, and a technique called positive end-
expiratory pressure (PEEP) to help push the fluid out of air sacs.

9. These are combined with continuing treatment of the original illness or injury.
Because people with ARDS are less-abled to fight lung infections, they may develop
bacterial pneumonia during the illness. Antibiotics are given to fight infection. Also,
supportive treatment, such as intravenous fluid or food, may be needed.
Original Source:- ARDS Market

10. CREDITS: This presentation template was
created by Slidesgo, including icons by
Flaticon, and infographics & images by
Freepik
Please keep this slide for attribution
info@delveinsight.com
ybhardwaj@delveinsight.com
+91-9650213330
Do You Have Any Question or Query?

11. CREDITS: This presentation template was
created by Slidesgo, including icons by
Flaticon, and infographics & images by
Freepik
Thanks!